Quicking Biotech Co., Ltd. stands as a distinguished provider of comprehensive animal testing services, catering to the rigorous demands of preclinical research across multiple industries. Founded in 2006, the company has built an exceptional reputation for delivering high-quality, reliable data that supports the development of pharmaceuticals, medical devices, and consumer products. The organization is deeply committed to scientific excellence and operational integrity, ensuring that every study conducted meets the highest standards of accuracy and reproducibility. When clients choose Quicking Biotech, they gain access to a partner that understands the critical role animal testing plays in advancing human and animal health. The company employs a diverse range of animal models including rodents, rabbits, dogs, and other species, carefully selected to match the specific requirements of each research protocol. This breadth of capability allows the team to address complex scientific questions across therapeutic areas with confidence and precision. Every study is designed with meticulous attention to detail, from initial protocol development through final data reporting, ensuring that results are both scientifically valid and regulatory ready. By combining technical expertise with a client-centered approach, Quicking Biotech has become a trusted partner for organizations seeking to navigate the complexities of preclinical development.

Quicking Biotech provides an extensive portfolio of animal testing services that cover the full spectrum of preclinical research needs, from early discovery through late-stage development. Pharmacokinetics studies are a cornerstone of the offering, enabling clients to understand how a candidate compound is absorbed, distributed, metabolized, and excreted within living systems over time. Toxicology studies are equally vital, as they help identify potential safety concerns and establish dose-limiting toxicities that inform later clinical trials. Efficacy and safety assessments are conducted with the same rigorous standards, giving sponsors clear evidence of whether a therapeutic agent produces the intended biological effect without causing unacceptable harm. The company also excels in custom study design, working closely with clients to create protocols that address unique scientific questions, unusual dosing regimens, or specialized biomarkers. Each study is supported by validated analytical methods, state-of-the-art instrumentation, and a highly trained technical staff that ensures data integrity at every step. Whether a client needs a standard single-dose toxicity study or a complex multi-species investigation, Quicking Biotech has the infrastructure and expertise to deliver. The company also supports clients preparing for regulatory submissions by providing comprehensive study reports that align with international guidelines. This full-service capability allows sponsors to consolidate their preclinical work with a single, reliable partner, saving time and reducing the complexity of study management.

One of the most compelling reasons to choose Quicking Biotech for your animal testing needs is the company's unwavering commitment to Good Laboratory Practice (GLP) compliance, which forms the foundation of all regulated preclinical work. GLP compliance ensures that every study is conducted under controlled, auditable conditions, producing data that regulatory authorities such as the FDA, EMA, and NMPA accept without question. The regulatory support team at Quicking Biotech is highly experienced in assisting clients with preparations for interactions with these agencies, offering guidance on study design, data presentation, and documentation requirements. Beyond regulatory matters, the scientific team comprises PhD-level toxicologists, pharmacologists, and veterinarians who bring decades of combined experience to every project. These experts are skilled at troubleshooting unexpected results, refining study parameters, and interpreting complex datasets to extract meaningful conclusions. The facilities themselves are a point of distinction, featuring cutting-edge equipment for bioanalysis, histopathology, clinical pathology, and molecular biology all under one roof. This integration minimizes sample handling and transit time, reduces the risk of errors, and accelerates study timelines. Clients also benefit from transparent communication, regular progress updates, and a dedicated project manager who serves as a single point of contact throughout the study. By combining scientific rigor with operational efficiency, Quicking Biotech consistently meets or exceeds client expectations while maintaining competitive pricing.

Quality control at Quicking Biotech is not an afterthought but a fundamental principle embedded in every aspect of operations, beginning with comprehensive Standard Operating Procedures (SOPs) that govern all study activities. These SOPs cover everything from animal handling and dosing procedures to sample collection, data recording, and report generation, leaving no room for ambiguity or variation. All personnel undergo rigorous training on these procedures before they are permitted to participate in any study, and periodic refresher training ensures that skills remain current. The company also places exceptional emphasis on animal welfare and ethical standards, strictly adhering to the 3Rs principle of Replacement, Reduction, and Refinement. Every study protocol is reviewed by an Institutional Animal Care and Use Committee (IACUC) to ensure that the proposed work is scientifically justified and that the number of animals used is minimized without compromising statistical power. Facilities are regularly inspected by external accrediting bodies, and the company maintains full AAALAC accreditation as a mark of its dedication to humane animal care. Data reliability is further enhanced through a robust quality assurance unit that conducts independent audits of studies, facilities, and records on a continuous basis. Any deviations from approved protocols are documented, investigated, and corrected, with findings communicated transparently to the client. This multi-layered approach to quality gives sponsors confidence that the data they receive is accurate, reproducible, and fully defensible in any regulatory context.

Quicking Biotech's animal testing services support a wide array of industries, each with its own unique regulatory landscape and scientific demands. The pharmaceutical sector is a primary client base, relying on the company's expertise to evaluate new chemical entities, biologics, and gene therapies through all phases of preclinical development. Biotechnology firms, particularly those developing novel modalities such as antibody-drug conjugates or cell therapies, benefit from the company's ability to design customized studies that address complex mechanisms of action. Medical device manufacturers also turn to Quicking Biotech for biocompatibility testing, implantation studies, and local tolerance assessments required for regulatory clearance. In the consumer product arena, companies involved in animal testing cosmetics use the company's services to evaluate the safety of new formulations, ingredients, and delivery systems under controlled conditions. The company is also well-versed in the specific requirements of the agrochemical and veterinary medicine sectors, conducting studies that support product registration and safety labeling. For clients concerned about the draize test and other traditional methods, Quicking Biotech offers updated protocols that incorporate refinements to reduce animal distress while maintaining scientific validity. The company regularly engages with clients who advocate for no animal testing alternatives and supports the development of in vitro and in silico methods where appropriate. By serving such a broad range of industries, Quicking Biotech has accumulated extensive cross-sector knowledge that enriches every new project.

Quicking Biotech's depth of experience is best illustrated through real-world examples that demonstrate the company's ability to solve challenging scientific problems while adhering to tight timelines and budgets. In one notable project, a pharmaceutical sponsor needed a comprehensive 28-day oral toxicity study in rats to support an Investigational New Drug (IND) application for a novel oncology compound. The Quicking team designed a protocol that included toxicokinetic sampling, clinical pathology, histopathology, and immunophenotyping, with all data delivered three weeks ahead of the original schedule. The study revealed an unexpected finding of transient liver enzyme elevation, which the scientific team investigated further and determined to be an adaptive response rather than true hepatotoxicity, providing critical reassurance to the sponsor. In another case, a medical device company approached Quicking Biotech to conduct a series of implantation studies for a new vascular stent material requiring up to 180-day observation periods in multiple species. The team developed a customized surgical model, established detailed histopathological endpoints, and successfully completed all studies with zero adverse events and outstanding data quality. A third example involved a biotechnology firm developing a topical formulation for a dermatological condition, requiring a dermal irritation and sensitization study. The team employed an optimized Draize test protocol with refined scoring criteria and additional endpoints for cytokine analysis, generating data that exceeded regulatory expectations. These examples underscore the company's ability to handle diverse scientific challenges with creativity, precision, and a relentless focus on client success. Each case also benefited from close collaboration with the sponsor's own scientific team, ensuring that all study objectives were met or exceeded.

Initiating a partnership with Quicking Biotech for your animal testing needs is a straightforward process designed to minimize administrative burden and accelerate the path to study initiation. The first step is to submit an inquiry through the New Pagecontact form on the company website, where a dedicated business development representative will respond within one business day. During the initial consultation, the team will discuss your scientific objectives, preferred study design, species requirements, dosing schedule, endpoints, and any special regulatory deadlines that must be met. Following this conversation, Quicking Biotech will prepare a detailed study proposal that includes a full protocol outline, project timeline, cost estimate, and list of deliverables for your review. Once the proposal is accepted, a project manager is assigned and a kickoff meeting is scheduled to align all stakeholders on expectations, communication protocols, and milestone dates. The company prides itself on fast turnaround times for proposals, typically delivering them within three to five business days of the initial consultation. Throughout the study, clients receive regular progress reports and have 24/7 access to their data through a secure online portal. After study completion, a comprehensive final report is prepared, and the team remains available to support regulatory submissions or answer any follow-up questions. To request a quote or schedule a preliminary discussion, visit the Quicking BiotechHome page and click on the contact section, or reach out directly by phone or email as listed on the About Us page.

Quicking Biotech Co., Ltd. offers a compelling combination of scientific expertise, regulatory readiness, operational excellence, and ethical commitment that makes it a premier choice for organizations requiring reliable preclinical animal testing services. The company's comprehensive service portfolio covers pharmacokinetics, toxicology, efficacy and safety assessments, and custom study designs, all delivered under strict GLP compliance with full AAALAC accreditation. Clients benefit from a highly experienced scientific team, state-of-the-art facilities, and a quality management system that ensures every piece of data is accurate, auditable, and ready for regulatory review. The company serves a diverse range of industries, including pharmaceuticals, biotechnology, medical devices, and consumer products, and has a proven track record of successfully completing complex studies on time and within budget. For those concerned about the Draize test or other traditional animal testing cosmetics methods, Quicking Biotech offers refined protocols that prioritize animal welfare and support the development of alternative approaches. By choosing Quicking Biotech, sponsors gain a partner who is deeply invested in their success, providing transparent communication, flexible study design, and unwavering support from concept through submission. To learn more about how Quicking Biotech can support your next preclinical project, explore theProducts page for additional capabilities or visit the News page for the latest company updates and scientific insights.

Quicking Biotech employs a variety of animal models including rodents such as rats and mice, rabbits, dogs, and other species selected according to the specific scientific and regulatory requirements of each study. The choice of model is based on factors like the nature of the test compound, the target organ system, the route of administration, and the specific endpoints being assessed. All animal models are sourced from accredited breeders and maintained under controlled environmental conditions to ensure consistency and data quality. The company's scientific team provides expert guidance to help sponsors select the most appropriate model for their research objectives.

Yes, Quicking Biotech operates in full compliance with Good Laboratory Practice (GLP) standards as defined by the OECD and other international regulatory bodies. All studies conducted for regulatory submission purposes follow GLP protocols, including rigorous documentation, quality assurance audits, and equipment calibration procedures. The company's facilities are regularly inspected by regulatory authorities and external accrediting organizations. This GLP certification ensures that study data is accepted by agencies such as the FDA, EMA, and NMPA without additional validation requirements.

Yes, Quicking Biotech provides animal testing services specifically designed for cosmetics and personal care product safety evaluations, including dermal irritation, skin sensitization, ocular irritation, and repeated dose toxicity studies. The company uses refined protocols that incorporate the 3Rs principles to minimize animal use and distress. For ocular irritation assessments, the team employs updated methodology that reduces the number of animals required and includes humane endpoints. Sponsors in the cosmetics industry can also discuss in vitro alternatives with the scientific team to determine the most appropriate testing strategy for their products.

The Draize test is a traditional method used to evaluate the eye and skin irritation potential of substances, typically involving rabbits. Quicking Biotech does perform eye and skin irritation studies but uses modern, refined versions of the Draize test that incorporate fewer animals, lower test volumes, and earlier humane endpoints to minimize discomfort. The company also actively develops and validates alternative in vitro and ex vivo methods that can replace or reduce the need for animal-based irritation testing. Clients are encouraged to discuss their specific requirements with the scientific team to identify the most ethical and scientifically robust approach.

Yes, Quicking Biotech includes beagle dogs as one of the non-rodent species available for preclinical studies, particularly for toxicology, pharmacokinetics, and safety pharmacology evaluations. Beagles are commonly selected because of their size, temperament, and the extensive historical database available for this species. All beagle testing at Quicking Biotech is conducted under strict ethical protocols with environmental enrichment, social housing whenever possible, and continuous veterinary oversight. The company maintains compliance with all relevant animal welfare regulations for canine studies.

Quicking Biotech is committed to the 3Rs framework—Replacement, Reduction, and Refinement—and actively evaluates alternative methods before initiating any animal-based study. The scientific team reviews available in vitro assays, computer modeling approaches, and ex vivo techniques to determine whether they can fully or partially replace animal testing for each project. When complete replacement is not scientifically feasible, the company designs studies that use the minimum number of animals required to achieve statistical power and incorporates refinements to reduce pain and distress. This approach aligns with global regulatory trends that encourage the use of alternative methods wherever possible.

To receive an accurate quote from Quicking Biotech, you should provide information about the test article (compound name, formulation, stability), the study objectives (toxicity, pharmacokinetics, efficacy), preferred species and strain, route of administration, dosing duration, specific endpoints required, and any regulatory deadlines or submission targets. The company also needs to know if you require GLP compliance, special analytical methods, or any additional services such as histopathology or bioanalysis. The more detailed your initial request, the more precise and timely the proposal will be. You can submit all this information through theNew Page contact form for a rapid response.

Study timelines at Quicking Biotech vary widely depending on the type, complexity, and duration of the animal test required. A standard acute toxicity study with a 14-day observation period may be completed in 6 to 8 weeks including protocol development, animal acclimation, dosing, sample analysis, and final reporting. A repeated-dose 28-day toxicology study typically requires 10 to 14 weeks, while chronic studies lasting 6 to 12 months naturally take longer. The company provides a detailed timeline during the proposal stage and works closely with clients to prioritize studies that have tight regulatory deadlines. Rush services are available for qualified projects at an additional cost.

Yes, Quicking Biotech offers comprehensive regulatory support services to help clients prepare for submissions to the FDA, NMPA, EMA, and other global regulatory authorities. The regulatory team reviews study designs for alignment with agency guidelines, prepares study reports in the required format, and assists with responses to regulatory questions during the review process. The company also provides expert advice on bridging studies, non-clinical development plans, and data packages required for different phases of drug or device development. This support is especially valuable for smaller companies that lack in-house regulatory expertise.

Animal welfare is a core priority at Quicking Biotech, and the company operates under an Institutional Animal Care and Use Committee (IACUC) that reviews all study protocols for ethical and scientific justification. The facilities are AAALAC accredited, which is the gold standard for humane animal care in research. All personnel receive mandatory training in animal handling, enrichment practices, and pain management. The company implements environmental enrichment programs, provides social housing for compatible species, and uses the most refined techniques available to minimize pain and distress. Regular veterinary monitoring ensures that any animal showing signs of suffering receives immediate intervention, including early euthanasia if necessary.